Details
Stereochemistry | ACHIRAL |
Molecular Formula | C12H17N4OS |
Molecular Weight | 265.355 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 1 |
SHOW SMILES / InChI
SMILES
CC1=C(CCO)SC=[N+]1CC2=C(N)N=C(C)N=C2
InChI
InChIKey=JZRWCGZRTZMZEH-UHFFFAOYSA-N
InChI=1S/C12H17N4OS/c1-8-11(3-4-17)18-7-16(8)6-10-5-14-9(2)15-12(10)13/h5,7,17H,3-4,6H2,1-2H3,(H2,13,14,15)/q+1
Molecular Formula | C12H16N4OS |
Molecular Weight | 264.347 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Thiamine, also known as vitamin B1, plays a key role in the human metabolism. It is present in many dietary sources such as meats, eggs, fish, beans and peas, nuts, and whole grains. Upon administration thiamine is converted by thiamine
pyrophosphokinase-1 (TPK1) to the active form, thiamine pyrophosphate, which serves as a cofactor for enzymes involved in the TCA cycle and the non-oxidative part of the pentose phosphate pathway. The lack of thiamine may cause the thiamine deficiency. The classical syndrome caused primarily by thiamine deficiency in humans is beriberi, however, symptoms of thiamine deficiency also include congestive heart failure, metabolic acidosis, confusion, ataxia and seizures. Thiamine is a component of many vitamin complexes, which are approved for the treatmen and prevention of general vitamin deficiency, including the thiamine deficiency.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7120152
Curator's Comment: The transport of thiamine across the blood brain barrier was shown in rats.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Q9H3S4 Gene ID: 27010.0 Gene Symbol: TPK1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/16550223 |
|||
Target ID: GO:0005975 |
|||
Target ID: WP408 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | M.V.I.-12 Approved UseM.V.I.-12 Unit Vial, is indicated for the prevention of vitamin deficiency in adults and children aged 11 years and above who are on warfarin anticoagulant therapy receiving home parenteral nutrition. Launch Date1953 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
40 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
39 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
95 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
113 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
386 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
397 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
214 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
177 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
623 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
612 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
2046 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
2059 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.92 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
4.78 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
2.97 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes | ||||
Sources: https://go.drugbank.com/drugs/DB00152 |
yes | |||
Sources: https://go.drugbank.com/drugs/DB00152 |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://go.drugbank.com/drugs/DB00152 |
yes |
PubMed
Title | Date | PubMed |
---|---|---|
[Evaluation of vitamin and immune status of patients with chronic palatal tonsillitis]. | 2001 |
|
Rapid diagnosis of alcoholic ketoacidosis by proton NMR. | 2001 Apr |
|
Severe metabolic acidosis and heart failure due to thiamine deficiency. | 2001 Apr |
|
Suppression of the accumulation of triosephosphates and increased formation of methylglyoxal in human red blood cells during hyperglycaemia by thiamine in vitro. | 2001 Apr |
|
[Chronic alcohol abuse. Benfotiamine in alcohol damage is a must]. | 2001 Apr 19 |
|
Aroma extract dilution analysis of a beeflike process flavor from extruded enzyme-hydrolyzed soybean protein. | 2001 Feb |
|
Evidence for non-enzymatic glycosylation in Escherichia coli. | 2001 Feb |
|
Reaction mechanism for mammalian pyruvate dehydrogenase using natural lipoyl domain substrates. | 2001 Feb 15 |
|
Phylogenetic analyses and comparative genomics of vitamin B6 (pyridoxine) and pyridoxal phosphate biosynthesis pathways. | 2001 Jan |
|
Phosphorylation of 1-deoxy-D-xylulose by D-xylulokinase of Escherichia coli. | 2001 Jan |
|
Thiamine-responsive megaloblastic anemia syndrome: a disorder of high-affinity thiamine transport. | 2001 Jan-Feb |
|
Effects of glucose, vitamins, and DO concentrations on pyruvate fermentation using Torulopsis glabrata IFO 0005 with metabolic flux analysis. | 2001 Jan-Feb |
|
Use of vitamin supplements and cataract: the Blue Mountains Eye Study. | 2001 Jul |
|
Sulphoacetaldehyde sulpho-lyase (EC 4.4.1.12) from Desulfonispora thiosulfatigenes: purification, properties and primary sequence. | 2001 Jul 15 |
|
No association between DLST gene and Alzheimer's disease or Wernicke-Korsakoff syndrome. | 2001 Jul-Aug |
|
The crystal structure of yeast thiamin pyrophosphokinase. | 2001 Jun |
|
Severe lactic acidosis and thiamine administration in an HIV-infected patient on HAART. | 2001 Jun |
|
Wernicke's encephalopathy in patients with hyperemesis gravidarum. | 2001 Mar |
|
[Isolation, purification and properties of acetolactate synthase from cultured Lactococcus lactis]. | 2001 Mar-Apr |
|
The value of oral thiamine. | 2001 Mar-Apr |
|
[Other drugs administered with TPN solution]. | 2001 May |
|
[Metabolic acidosis induced by TPN]. | 2001 May |
|
[Solutions for the hyperalimentation]. | 2001 May |
|
Early recognition of acute cardiovascular beriberi by interpretation of hemodynamics. | 2001 May |
|
Wernicke's encephalopathy in a non-alcoholic man: case report and brief review. | 2001 May |
|
Stability of thiamine and vitamins E and A during storage of enteral feeding formula. | 2001 May |
|
The role of the cysteine residues of ThiI in the generation of 4-thiouridine in tRNA. | 2001 Sep 7 |
Patents
Sample Use Guides
The starting dose (as a component of M.V.I.–12) is one 10 mL daily dose added directly to an intravenous fluid.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10516094
Human Caco-2 cells were incubated (37 Celsius) in Krebs-Ringer buffer (pH 7.4) for different periods of time in the presence of 0.1 uM and 10 uM thiamine. The uptake study demonstrated that thiamine is transported across the cell membrane with Michaelis-Menten constant of 3.18 uM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:13:14 GMT 2025
by
admin
on
Mon Mar 31 18:13:14 GMT 2025
|
Record UNII |
4ABT0J945J
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
4ABT0J945J
Created by
admin on Mon Mar 31 18:13:14 GMT 2025 , Edited by admin on Mon Mar 31 18:13:14 GMT 2025
|
PRIMARY | |||
|
70-16-6
Created by
admin on Mon Mar 31 18:13:14 GMT 2025 , Edited by admin on Mon Mar 31 18:13:14 GMT 2025
|
PRIMARY | |||
|
DTXSID50220251
Created by
admin on Mon Mar 31 18:13:14 GMT 2025 , Edited by admin on Mon Mar 31 18:13:14 GMT 2025
|
PRIMARY | |||
|
18385
Created by
admin on Mon Mar 31 18:13:14 GMT 2025 , Edited by admin on Mon Mar 31 18:13:14 GMT 2025
|
PRIMARY | |||
|
4ABT0J945J
Created by
admin on Mon Mar 31 18:13:14 GMT 2025 , Edited by admin on Mon Mar 31 18:13:14 GMT 2025
|
PRIMARY | |||
|
1546268
Created by
admin on Mon Mar 31 18:13:14 GMT 2025 , Edited by admin on Mon Mar 31 18:13:14 GMT 2025
|
PRIMARY | RxNorm | ||
|
1130
Created by
admin on Mon Mar 31 18:13:14 GMT 2025 , Edited by admin on Mon Mar 31 18:13:14 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |